Share on StockTwits
 

Stock analysts at Barclays upped their price target on shares of Gilead Sciences (NASDAQ:GILD) from $90.00 to $95.00 in a report issued on Friday, American Banking and Market News reports. The firm currently has an “overweight” rating on the stock. Barclays’ target price indicates a potential upside of 14.72% from the stock’s previous close.

A number of other firms have also recently commented on GILD. Analysts at Argus raised their price target on shares of Gilead Sciences from $84.00 to $90.00 in a research note on Monday, February 10th. They now have a “buy” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, February 5th. They now have a $132.00 price target on the stock. Finally, analysts at Summer Street reiterated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, February 5th. Two equities research analysts have rated the stock with a hold rating and twenty-six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $85.73.

Gilead Sciences (NASDAQ:GILD) traded up 0.31% during mid-day trading on Friday, hitting $83.065. The stock had a trading volume of 7,197,194 shares. Gilead Sciences has a one year low of $41.60 and a one year high of $84.40. The stock has a 50-day moving average of $78.76 and a 200-day moving average of $69.36. The company has a market cap of $127.5 billion and a P/E ratio of 45.75.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $0.55 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.05. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 20.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $3.75 EPS for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.